Matt Zeller, country president of Novartis Australia and New Zealand, said, “The impact of CVD in Australia is devastating, claiming one life every 12 minutes. Now, Leqvio is available on the PBS and this first-in-class treatment option has the potential to transform patient care and help improve the lives of individuals living with CVD.”
Novartis welcomes the listing of first-in-class cholesterol-lowering therapy
April 2, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
